LYC-55716
oral RORγ nuclear receptor agonist 450 mg BID, phase I/II, cancer from change in MoA of RORγ antagonist + opt. Journal of Medicinal Chemistry Lycera
Molecules of the Month - September 2021
Molecules of the Month
- ETX0462
- milvexian
- GSK3685032
- JNJ-64619178
- vimseltinib
- ARD-2585
- AZD5305
- SAR247799
- IM156
- BMS-986158
- JNJ-67569762
- FRM-024
- LYC-55716
- S-600918